ENALAPRILAT SUMMARY
ENALAPRILAT INJECTION
Enalaprilat Injection is a sterile aqueous solution for intravenous administration. Enalaprilat is an angiotensin converting enzyme inhibitor.
Enalaprilat Injection is indicated for the treatment of hypertension when oral therapy is not practical.
Enalaprilat Injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension.
In using Enalaprilat Injection, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that Enalaprilat Injection does not have a similar risk. (See WARNINGS.)
In considering use of Enalaprilat Injection, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema.)
|
NEWS HIGHLIGHTSMedia Articles Related to Enalaprilat
Seasoning May Cut Salt Needs in Hypertension (CME/CE)
Source: MedPage Today Primary Care [2013.05.18]
SAN FRANCISCO (MedPage Today) -- A greater taste for salt among older hypertensive adults might be sated by seasoning instead, a small experimental study showed.
Surprising Findings On Hypertension In Adolescents
Source: Hypertension News From Medical News Today [2013.05.07]
Teenagers with high blood pressure appear to have better psychological adjustment and enjoy higher quality of life than those with normal blood pressure, suggests a study in the May issue of Psychosomatic Medicine: Journal of Biobehavioral Medicine, the official journal of the American Psychosomatic Society...
Safety-Net Clinics Face Challenges Controlling Hypertension In Their Patients
Source: Hypertension News From Medical News Today [2013.04.19]
Federally funded safety-net clinics for the uninsured lag behind other health care providers in controlling blood pressure among the low-income patients who rely on them for care, a new Michigan State University analysis suggests...
Relationship Between Obesity, Heart Disease And Hypertension
Source: Hypertension News From Medical News Today [2013.04.13]
Obesity, heart disease, and high blood pressure (hypertension) are all related, but understanding the molecular pathways that underlie cause and effect is complicated...
Preeclampsia (Pregnancy Induced Hypertension)
Source: MedicineNet Hydronephrosis Specialty [2012.05.21]
Title: Preeclampsia (Pregnancy Induced Hypertension)
Category: Diseases and Conditions
Created: 11/14/1998 4:06:00 PM
Last Editorial Review: 5/21/2012 12:00:00 AM
Published Studies Related to Enalaprilat
Myocardial protection with enalaprilat in patients unresponsive to ischemic preconditioning during percutaneous coronary intervention. [2008.12]
Cardioprotection due to angiotensin enzyme inhibitors is attributed, at least in part, to the inhibition of bradykinin breakdown and the preconditioning effect of the elevated endogenous bradykinin level. We have previously shown that in patients undergoing percutaneous coronary intervention, one 120-second balloon inflation is insufficient to precondition the heart...
Pretreatment with intracoronary enalaprilat protects human myocardium during percutaneous coronary angioplasty. [2007.04.17]
OBJECTIVES: We tested the hypothesis that enalaprilat induces preconditioning (PC)-mimetic actions in patients with stable coronary artery disease. BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors increase the bioavailability of bradykinin, which induces cardiac PC... CONCLUSIONS: Pretreatment with enalaprilat attenuates the manifestations of myocardial ischemia during angioplasty. This is the first in vivo evidence showing that an ACE inhibitor protects human myocardium, possibly via PC-mimetics actions, a novel property that might explain the cardioprotective actions of these drugs.
Clinical Trials Related to Enalaprilat
Comparison of the Antihypertensive Efficacy of Valsartan and Enalapril After Missing One Dose [Completed]
This study was designed in order to evaluate the blood pressure lowering effect of valsartan
compared to enalapril over 24 hours after skipping one daily dose. Both drugs act on the
renin-angiotensin-aldosterone system (RAAS) and are widely use for the treatment of
hypertension. Previous studies had a significant limitation: the effect of a missing dose was
not evaluated after the whole 24 hours post missing dose period (48 hours after last taken
dose), and as a result, it does not imitate the real life situation of a missing dose.
Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer [Recruiting]
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Enalapril maleate may help protect heart cells from the side effects of
chemotherapy. It is not yet known whether giving enalapril maleate before or after
doxorubicin hydrochloride is more effective in treating women with breast cancer.
PURPOSE: This randomized clinical trial is studying giving enalapril maleate together with
doxorubicin hydrochloride to see how well it works in treating women with breast cancer.
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure [Recruiting]
The study will evaluate the efficacy and safety of both aliskiren monotherapy and
aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity
and mortality in patients with chronic heart failure (NYHA Class II - IV.
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age [Recruiting]
The purpose of this study is to evaluate in a randomized, double-blind fashion, the
long-term safety, tolerability and efficacy profile of aliskiren compared to the active
comparator enalapril in children, 6 - 17 years old with hypertension (msSBP ≥ 95th
percentile for age, gender and height, at baseline in study CSPP100A2365). Patients will be
randomized to receive either aliskiren or enalapril. Weight-group based doses of aliskiren
or enalapril will be administered once daily and children will receive study medication in a
double-blind manner. This study is being conducted to support monotherapy registration of
aliskiren for the treatment of hypertension in pediatric patients 6-17 years of age (age at
baseline in Study CSPP100A2365).
The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients [Recruiting]
A prospective, randomized, open-label, Single-center clinical trial to determine whether
Enalapril or Enalapril plus Losartan effect on Peritoneal membrane transportation.
|
